Jacobs Levy Equity Management
NPCE icon

Jacobs Levy Equity Management’s Neuropace NPCE Stock Holding History

Jacobs Levy Equity Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-51,972
Closed -$579K – 1064
2025
Q2 		$579K Buy
51,972
+165
+0.3% +$2.06K ﹤0.01% 863
2025
Q1 		$637K Sell
51,807
-5,289
-9% -$66.2K ﹤0.01% 890
2024
Q4 		$639K Buy
+57,096
New +$496K ﹤0.01% 776
2023
Q1 		– Sell
-23,692
Closed -$35.3K – 1032
2022
Q4 		$35.3K Buy
+23,692
New +$52.6K ﹤0.01% 931

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Jacobs Levy Equity Management's NPCE Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 51,972 shares — an estimated $579K sold.

Jacobs Levy Equity Management first reported a position in NPCE in Q4 2022 and held it in 4 quarters. The position peaked at $639K in Q4 2024. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 51,972 Neuropace shares in Q3 2025, an estimated $579K.
  • Jacobs Levy Equity Management first reported a position in Neuropace in Q4 2022 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Neuropace position peaked at $639K in Q4 2024.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.